AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30269100 — intervention group
Group type: COMPARATOR
Intervention: 0 min adaptation after ambient light exposure
Number of subjects: 50
Study 30269100 — intervention group
Group type: COMPARATOR
Intervention: 5 min adaptation after ambient light exposure
Number of subjects: 50
Study 30269100 — intervention group
Group type: COMPARATOR
Intervention: 10 min adaptation after ambient light exposure
Number of subjects: 50
Study 30269100 — intervention group
Group type: COMPARATOR
Intervention: 15 min adaptation after ambient light exposure
Number of subjects: 50
Study 30269100 — intervention group
Group type: COMPARATOR
Intervention: 20 min adaptation after ambient light exposure
Number of subjects: 50
Study 30269100 — intervention group
Group type: COMPARATOR
Intervention: 30 min adaptation after ambient light exposure
Number of subjects: 50
Study 30269100 — intervention group
Group type: COMPARATOR
Intervention: 0 min adaptation after bright light exposure
Number of subjects: 50
Study 30269100 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min adaptation after bright light exposure
Number of subjects: 50
Study 30269100 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min adaptation after bright light exposure
Number of subjects: 50
Study 30269100 — intervention group
Group type: COMPARATOR
Intervention: 0 min adaptation after ambient light exposure in choroideremia
Number of subjects: 50
Study 30269100 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min adaptation after ambient light exposure in choroideremia
Number of subjects: 50
Study 29381917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical kyphosis patients
Number of subjects: 60
Study 29381917 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 60
Study 26094695 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymalfasin (1.6 mg twice a week for 12 months)
Number of subjects: 0
Study 26094695 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22420329 — intervention group
Group type: EXPERIMENTAL
Intervention: DC + M2 (denture cleanser for 3 min with 2 min microwave irradiation)
Number of subjects: 7
Study 22420329 — intervention group
Group type: EXPERIMENTAL
Intervention: DC + M3 (denture cleanser for 3 min with 3 min microwave irradiation)
Number of subjects: 7
Study 22420329 — intervention group
Group type: EXPERIMENTAL
Intervention: DW + M3 (distilled water for 3 min with 3 min microwave irradiation)
Number of subjects: 7
Study 22420329 — intervention group
Group type: COMPARATOR
Intervention: DW (distilled water for 3 min with 0 min microwave irradiation)
Number of subjects: 7
Study 22420329 — intervention group
Group type: COMPARATOR
Intervention: DW + M1 (distilled water for 3 min with 1 min microwave irradiation)
Number of subjects: 7
Study 22420329 — intervention group
Group type: COMPARATOR
Intervention: DC (denture cleanser for 3 min with 0 min microwave irradiation)
Number of subjects: 7
Study 21613558 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D concentrations (≥52 nmol/L)
Number of subjects: 292
Study 21613558 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D concentrations
Number of subjects: 292
Study 19220313 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20-40 mg/day
Number of subjects: 40
Study 19220313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17124558 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified omega-3 fatty acid ethylesters (omega-3-acid ethyl esters 90=Zodin)
Number of subjects: 0
Study 12510010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin (CCK-B receptor agonist)
Number of subjects: 0
Study 10881555 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary cognitive tasks performed concurrently with secondary executive tasks
Number of subjects: 0
Study 10881555 — intervention group
Group type: COMPARATOR
Intervention: Secondary executive tasks
Number of subjects: 0
Study 9394638 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing unladen
Number of subjects: 0
Study 9394638 — intervention group
Group type: EXPERIMENTAL
Intervention: Handling a load
Number of subjects: 0
Study 9394638 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding a load with one hand on the shoulder
Number of subjects: 0
Study 9394638 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased separation of the feet
Number of subjects: 0
Study 8245901 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 187
Study 8245901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 3927356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cianopramine (n = 20, mean daily dose 3.3 +/- 0.6 mg)
Number of subjects: 60
Study 3927356 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (n = 20, mean daily dose 86.4 +/- 21 mg)
Number of subjects: 60
Study 3927356 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 60
Study 30383646 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic left ventricular hypertrophy
Number of subjects: 17312
Study 30383646 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic left ventricular hypertrophy in males
Number of subjects: 17312
Study 30383646 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic left ventricular hypertrophy in females
Number of subjects: 17312
Study 30383646 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic left ventricular hypertrophy in patients with comorbid diabetes
Number of subjects: 17312
Study 26843483 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert raters (n = 5)
Number of subjects: 50
Study 26843483 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendees of the EULAR capillaroscopy course (n = 34)
Number of subjects: 50
Study 26843483 — intervention group
Group type: EXPERIMENTAL
Intervention: Novices after a 1-h course (n = 11)
Number of subjects: 50
Study 26843483 — intervention group
Group type: COMPARATOR
Intervention: Normal vs combined groups of abnormal and not evaluable capillaries (Expert raters)
Number of subjects: 50
Study 26843483 — intervention group
Group type: COMPARATOR
Intervention: Normal vs combined groups of abnormal and not evaluable capillaries (Attendees)
Number of subjects: 50
Study 26843483 — intervention group
Group type: COMPARATOR
Intervention: Normal vs combined groups of abnormal and not evaluable capillaries (Novices)
Number of subjects: 50
Study 26843483 — intervention group
Group type: EXPERIMENTAL
Intervention: Classifiable capillaries (Expert raters)
Number of subjects: 50
Study 26843483 — intervention group
Group type: EXPERIMENTAL
Intervention: Classifiable capillaries (Attendees)
Number of subjects: 50
Study 26843483 — intervention group
Group type: EXPERIMENTAL
Intervention: Classifiable capillaries (Novices)
Number of subjects: 50
Study 24846789 — intervention group
Group type: EXPERIMENTAL
Intervention: Smiling condition
Number of subjects: 0
Study 24846789 — intervention group
Group type: EXPERIMENTAL
Intervention: Frowning condition
Number of subjects: 0
Study 24846789 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 0
Study 22434327 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG) intervention, with training and weekly on-site support from coaches.
Number of subjects: 8
Study 20362342 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous immunizations (experimental group)
Number of subjects: 101
Study 20362342 — intervention group
Group type: COMPARATOR
Intervention: Sequential immunizations (control group)
Number of subjects: 101
Study 18543367 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 374
Study 15896512 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose (OF) 6 g daily for 15 days
Number of subjects: 41
Study 15896512 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (Control group)
Number of subjects: 41
Study 15896512 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 41
Study 15896512 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn patients
Number of subjects: 41
Study 12224473 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS to the common peroneal nerve
Number of subjects: 43
Study 12224473 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS to the cutaneous branches of the peroneal nerve
Number of subjects: 43
Study 12224473 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 43
Study 10065691 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (a selective dopamine D2‐receptor antagonist)
Number of subjects: 16
Study 10065691 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects, N=9)
Number of subjects: 16
Study 10065691 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OSAS
Number of subjects: 16
Study 8522792 — intervention group
Group type: EXPERIMENTAL
Intervention: Clothing ensemble HALF (half-sleeved shirts, knee-length trousers, sandals, hat)
Number of subjects: 7
Study 8522792 — intervention group
Group type: COMPARATOR
Intervention: Clothing ensemble LONG (long-sleeved shirts, long trousers, gloves, socks, walking shoes, hat)
Number of subjects: 7
Study 8522792 — intervention group
Group type: EXPERIMENTAL
Intervention: Clothing ensemble HALF
Number of subjects: 7
Study 8522792 — intervention group
Group type: COMPARATOR
Intervention: Clothing ensemble LONG
Number of subjects: 7
Study 1959848 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy (paravenous polidocanol [10 mg/ml] every 1 to 2 weeks until eradication)
Number of subjects: 286
Study 1959848 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (slow-release preparation in one daily dose adjusted to provide about 25% heart rate reduction)
Number of subjects: 286
Study 1959848 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sclerotherapy and propranolol
Number of subjects: 286
Study 1959848 — intervention group
Group type: COMPARATOR
Intervention: Control group (neither sclerotherapy nor propranolol)
Number of subjects: 286
Study 6112024 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine-exposure
Number of subjects: 40
Study 6112024 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine-no exposure
Number of subjects: 40
Study 6112024 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-exposure
Number of subjects: 40
Study 6112024 — intervention group
Group type: COMPARATOR
Intervention: Placebo-no exposure
Number of subjects: 40
Study 31483000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive caregiver education program (ICEP)
Number of subjects: 196
Study 31483000 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual education and guidance)
Number of subjects: 196
Study 28486851 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral weight-loss program (the TODAY Lifestyle Program)
Number of subjects: 234
Study 25312529 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure™ tissue fusion technology with the ForceTriad™ energy platform (LS)
Number of subjects: 146
Study 25312529 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST) - conventional electrosurgical pencil
Number of subjects: 146
Study 23386756 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced information group (received pamphlet and physiotherapy handout)
Number of subjects: 40
Study 23386756 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group
Number of subjects: 40
Study 23386756 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced information group
Number of subjects: 40
Study 23386756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 21750125 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/day
Number of subjects: 334
Study 21750125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 19042026 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 0.5-4 mg/day
Number of subjects: 111
Study 19042026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 15789141 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (COL; 20 g daily)
Number of subjects: 12
Study 15789141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; 20 g maltodextrin daily)
Number of subjects: 12
Study 12460229 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate
Number of subjects: 0
Study 12460229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate
Number of subjects: 0
Study 12460229 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study 12460229 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 10362390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (cold water immersion at 15 degrees C for 15 min immediately after exercise and every 12 h for 15 min for a total of seven sessions)
Number of subjects: 15
Study 10362390 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 15
Study 8926739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoid immunoassays with 100‐ng/mL cutoff
Number of subjects: 6
Study 8926739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoid immunoassays with 50‐ng/mL cutoff
Number of subjects: 6
Study 8926739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabinoid immunoassays with 20‐ng/mL cutoff
Number of subjects: 6
Study 8926739 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography‐mass spectrometry (GC‐MS)
Number of subjects: 6
Study 8926739 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial cannabinoid immunoassay with a 50‐ng/mL cutoff
Number of subjects: 6
Study 2031824 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with isobaric 0.5% bupivacaine
Number of subjects: 150
Study 2031824 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with hyperbaric 0.5% bupivacaine
Number of subjects: 150
Study 2031824 — intervention group
Group type: COMPARATOR
Intervention: Extradural anaesthesia with isobaric 0.5% bupivacaine
Number of subjects: 150
Study 7017486 — intervention group
Group type: EXPERIMENTAL
Intervention: guacetisal (Broncaspin)
Number of subjects: 26
Study 7017486 — intervention group
Group type: COMPARATOR
Intervention: bromexine
Number of subjects: 26
Study 30564950 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic follow-up at 6 months
Number of subjects: 219
Study 30564950 — intervention group
Group type: EXPERIMENTAL
Intervention: History of chronic heart failure at baseline
Number of subjects: 219
Study 28807915 — intervention group
Group type: COMPARATOR
Intervention: 14-day bismuth quadruple therapy
Number of subjects: 330
Study 28807915 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day hybrid therapy
Number of subjects: 330
Study 26537161 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc-C Total Disc Replacement
Number of subjects: 209
Study 26537161 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 209
Study 23572220 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP
Number of subjects: 378
Study 23572220 — intervention group
Group type: COMPARATOR
Intervention: LLA
Number of subjects: 378
Study 22051126 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted search group (librarian assistance)
Number of subjects: 18
Study 22051126 — intervention group
Group type: COMPARATOR
Intervention: Non-assisted (control) group
Number of subjects: 18
Study 19057518 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministered amlodipine 5 mg and atorvastatin 10 mg
Number of subjects: 668
Study 19057518 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 668
Study 19057518 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 668
Study 19057518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 668
Study 17324005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet 30 mg twice daily
Number of subjects: 21
Study 17324005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15107654 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0
Study 11870141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IvIg) treatment
Number of subjects: 58
Study 11870141 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 58
Study 11870141 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from IvIg treatment
Number of subjects: 58
Study 11870141 — intervention group
Group type: COMPARATOR
Intervention: Combined data from placebo treatment
Number of subjects: 58
Study 9850901 — intervention group
Group type: EXPERIMENTAL
Intervention: MDX‐RA (investigational immunotoxin)
Number of subjects: 0
Study 9850901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7856293 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-valent Klebsiella capsular polysaccharide vaccine and eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously
Number of subjects: 41
Study 7856293 — intervention group
Group type: COMPARATOR
Intervention: 24-valent Klebsiella capsular polysaccharide vaccine and eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered 14 days apart
Number of subjects: 41
Study 7856293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccination schedules
Number of subjects: 41
Study 2791807 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg)
Number of subjects: 41
Study 2791807 — intervention group
Group type: COMPARATOR
Intervention: Saline/Placebo
Number of subjects: 41
Study 1217683 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 1% with adrenaline
Number of subjects: 0
Study 1217683 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with adrenaline
Number of subjects: 0
Study 31894414 — intervention group
Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 100
Study 31894414 — intervention group
Group type: COMPARATOR
Intervention: Exercise + Protein (EP)
Number of subjects: 100
Study 31894414 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 100
Study 30187632 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/d, regular group (n = 25)
Number of subjects: 50
Study 30187632 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/d, intermittent group (n = 25)
Number of subjects: 50
Study 26757022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebralcare Granule (CG)
Number of subjects: 3251
Study 26757022 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 3251
Study 26215431 — intervention group
Group type: EXPERIMENTAL
Intervention: HEI plus fesoterodine
Number of subjects: 682
Study 26215431 — intervention group
Group type: COMPARATOR
Intervention: fesoterodine alone (control)
Number of subjects: 682
Study 26215431 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 682
Study 24135593 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 µg of AFB1/kg diet (750 ppb of AFB1)
Number of subjects: 0
Study 24135593 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 µg of AFB1/kg diet (75 ppb of AFB1)
Number of subjects: 0
Study 24135593 — intervention group
Group type: COMPARATOR
Intervention: Control diet (no AFB1)
Number of subjects: 0
Study 21458097 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (once-daily injection for 16 weeks)
Number of subjects: 30
Study 21458097 — intervention group
Group type: COMPARATOR
Intervention: Control (normal glycemic subjects)
Number of subjects: 30
Study 21458097 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM (pre-treatment)
Number of subjects: 30
Study 18358692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS combined with pergolide
Number of subjects: 12
Study 18358692 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS combined with placebo
Number of subjects: 12
Study 16241018 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA)
Number of subjects: 260
Study 16241018 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia via facemask (GA-M)
Number of subjects: 260
Study 16241018 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia via endotracheal intubation (GA-T)
Number of subjects: 260
Study 12018920 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 130
Study 12018920 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg
Number of subjects: 130
Study 9665421 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1200 mg/day)
Number of subjects: 32
Study 9665421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7655766 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranidipine (1‐2 mg) once daily for 1‐2 weeks
Number of subjects: 9
Study 2816361 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment
Number of subjects: 24
Study 2816361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1139128 — intervention group
Group type: EXPERIMENTAL
Intervention: Small doses of subcutaneous sodium heparin
Number of subjects: 64
Study 1139128 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study 31862764 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 57
Study 31862764 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 57
Study 29773696 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) plus usual care (UC)
Number of subjects: 39
Study 29773696 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 39
Study 27230862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) + Usual Care (UC) for 16 weeks
Number of subjects: 42
Study 27230862 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) alone for 16 weeks
Number of subjects: 42
Study 24809242 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on bitopertin therapy
Number of subjects: 0
Study 24809242 — intervention group
Group type: EXPERIMENTAL
Intervention: NSFS
Number of subjects: 0
Study 22825283 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 20